STAAR Surgical Hits 4 Million ICLs Sold, Signaling Laser Vision Correction Decline
Event summary
- STAAR Surgical has sold over 4 million Implantable Collamer® Lenses (ICLs) globally.
- The company surpassed 1 million ICLs in 2019, 2 million in 2022, and 3 million in 2024.
- The average ICL patient is 32 years old, according to 2025 data.
- EVO ICL is the only implantable lens made with Collamer, a proprietary biocompatible material.
The big picture
STAAR Surgical's milestone of 4 million ICLs sold underscores a broader industry shift towards lens-based refractive surgery. This trend is driven by patient and surgeon preference for minimally invasive procedures that preserve corneal integrity. The company's proprietary Collamer material and expanded regulatory approvals position it as a leader in this evolving market.
What we're watching
- Market Shift
- How the shift from laser-based to lens-based vision correction will impact STAAR's market share and revenue growth.
- Regulatory Progress
- Whether expanded regulatory indications for EVO ICL in key markets will further drive patient adoption.
- Competitive Dynamics
- The pace at which competitors develop similar lens-based solutions to challenge STAAR's dominance.
Related topics